FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132733182> ?p ?o ?g. }

• W2132733182 endingPage "197" @default.
• W2132733182 startingPage "191" @default.
• W2132733182 abstract "Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated both gemfibrozil and its major metabolite, an acyl-glucuronide (gemfibrozil 1-O-beta-glucuronide) as direct-acting and metabolism-dependent inhibitors of the major drug-metabolizing cytochrome P450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) in human liver microsomes. Gemfibrozil most potently inhibited CYP2C9 (IC50 of 30 microM), whereas gemfibrozil glucuronide most potently inhibited CYP2C8 (IC50 of 24 microM). Unexpectedly, gemfibrozil glucuronide, but not gemfibrozil, was found to be a metabolism-dependent inhibitor of CYP2C8 only. The IC50 for inhibition of CYP2C8 by gemfibrozil glucuronide decreased from 24 microM to 1.8 microM after a 30-min incubation with human liver microsomes and NADPH. Inactivation of CYP2C8 by gemfibrozil glucuronide required NADPH, and proceeded with a K(I) (inhibitor concentration that supports half the maximal rate of enzyme inactivation) of 20 to 52 microM and a k(inact) (maximal rate of inactivation) of 0.21 min(-1). Potent inhibition of CYP2C8 was also achieved by first incubating gemfibrozil with alamethicin-activated human liver microsomes and UDP-glucuronic acid (to form gemfibrozil glucuronide), followed by a second incubation with NADPH. Liquid chromatography-tandem mass spectrometry analysis established that human liver microsomes and recombinant CYP2C8 both convert gemfibrozil glucuronide to a hydroxylated metabolite, with oxidative metabolism occurring on the dimethylphenoxy moiety (the group furthest from the glucuronide moiety). The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone." @default.
• W2132733182 created "2016-06-24" @default.
• W2132733182 creator A5028997463 @default.
• W2132733182 creator A5034601758 @default.
• W2132733182 creator A5035374461 @default.
• W2132733182 creator A5038814197 @default.
• W2132733182 creator A5052044457 @default.
• W2132733182 creator A5053022132 @default.
• W2132733182 creator A5057012991 @default.
• W2132733182 creator A5072451359 @default.
• W2132733182 date "2005-11-18" @default.
• W2132733182 modified "2023-10-17" @default.
• W2132733182 title "GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS" @default.
• W2132733182 cites W1542232001 @default.
• W2132733182 cites W1550877969 @default.
• W2132733182 cites W1558276030 @default.
• W2132733182 cites W1581885355 @default.
• W2132733182 cites W1983687170 @default.
• W2132733182 cites W1996048503 @default.
• W2132733182 cites W2007465373 @default.
• W2132733182 cites W2009484232 @default.
• W2132733182 cites W2010241890 @default.
• W2132733182 cites W2027970944 @default.
• W2132733182 cites W2041058912 @default.
• W2132733182 cites W2048796575 @default.
• W2132733182 cites W2058184306 @default.
• W2132733182 cites W2068150904 @default.
• W2132733182 cites W2069390464 @default.
• W2132733182 cites W2070098436 @default.
• W2132733182 cites W2100744461 @default.
• W2132733182 cites W2151471516 @default.
• W2132733182 cites W2152964734 @default.
• W2132733182 cites W2158607621 @default.
• W2132733182 cites W2163360636 @default.
• W2132733182 cites W2163711771 @default.
• W2132733182 cites W2170698056 @default.
• W2132733182 cites W2172069516 @default.
• W2132733182 cites W2172236497 @default.
• W2132733182 cites W4235466386 @default.
• W2132733182 cites W4250397481 @default.
• W2132733182 doi "https://doi.org/10.1124/dmd.105.007633" @default.
• W2132733182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16299161" @default.
• W2132733182 hasPublicationYear "2005" @default.
• W2132733182 type Work @default.
• W2132733182 sameAs 2132733182 @default.
• W2132733182 citedByCount "303" @default.
• W2132733182 countsByYear W21327331822012 @default.
• W2132733182 countsByYear W21327331822013 @default.
• W2132733182 countsByYear W21327331822014 @default.
• W2132733182 countsByYear W21327331822015 @default.
• W2132733182 countsByYear W21327331822016 @default.
• W2132733182 countsByYear W21327331822017 @default.
• W2132733182 countsByYear W21327331822018 @default.
• W2132733182 countsByYear W21327331822019 @default.
• W2132733182 countsByYear W21327331822020 @default.
• W2132733182 countsByYear W21327331822021 @default.
• W2132733182 countsByYear W21327331822022 @default.
• W2132733182 countsByYear W21327331822023 @default.
• W2132733182 crossrefType "journal-article" @default.
• W2132733182 hasAuthorship W2132733182A5028997463 @default.
• W2132733182 hasAuthorship W2132733182A5034601758 @default.
• W2132733182 hasAuthorship W2132733182A5035374461 @default.
• W2132733182 hasAuthorship W2132733182A5038814197 @default.
• W2132733182 hasAuthorship W2132733182A5052044457 @default.
• W2132733182 hasAuthorship W2132733182A5053022132 @default.
• W2132733182 hasAuthorship W2132733182A5057012991 @default.
• W2132733182 hasAuthorship W2132733182A5072451359 @default.
• W2132733182 hasConcept C109650736 @default.
• W2132733182 hasConcept C115368759 @default.
• W2132733182 hasConcept C134651460 @default.
• W2132733182 hasConcept C181199279 @default.
• W2132733182 hasConcept C185592680 @default.
• W2132733182 hasConcept C2776980637 @default.
• W2132733182 hasConcept C2777477808 @default.
• W2132733182 hasConcept C2778163477 @default.
• W2132733182 hasConcept C2778670441 @default.
• W2132733182 hasConcept C2779186261 @default.
• W2132733182 hasConcept C2779415389 @default.
• W2132733182 hasConcept C2779907587 @default.
• W2132733182 hasConcept C526171541 @default.
• W2132733182 hasConcept C55493867 @default.
• W2132733182 hasConcept C62231903 @default.
• W2132733182 hasConcept C86803240 @default.
• W2132733182 hasConcept C87644729 @default.
• W2132733182 hasConcept C98274493 @default.
• W2132733182 hasConceptScore W2132733182C109650736 @default.
• W2132733182 hasConceptScore W2132733182C115368759 @default.
• W2132733182 hasConceptScore W2132733182C134651460 @default.
• W2132733182 hasConceptScore W2132733182C181199279 @default.
• W2132733182 hasConceptScore W2132733182C185592680 @default.
• W2132733182 hasConceptScore W2132733182C2776980637 @default.
• W2132733182 hasConceptScore W2132733182C2777477808 @default.
• W2132733182 hasConceptScore W2132733182C2778163477 @default.
• W2132733182 hasConceptScore W2132733182C2778670441 @default.
• W2132733182 hasConceptScore W2132733182C2779186261 @default.
• W2132733182 hasConceptScore W2132733182C2779415389 @default.
• W2132733182 hasConceptScore W2132733182C2779907587 @default.
• W2132733182 hasConceptScore W2132733182C526171541 @default.

• next